fda glp-1 New Pill Foundayo (Orforglipron) Gets Approval for Obesity US FDA accepts Novo Nordisk's

This policy shift increases the likelihood that clinicians will need to document comorbid indications such as type 2 diabetes or cardiovascular disease to justify continued prescribing under covered diagnoses

Glucose Support Capsules Supports normal blood sugar levels and energy levels

Nirmatrelvir and the risk of post-acute sequelae of COVID-19

PIONEER 1: randomized clinical trial comparing the efficacy and safety of oral semaglutide monotherapy with placebo in patients with type 2 diabetes

This post breaks down what you need to know: how these medications work, what the key evidence shows, and most importantly, how to recognize and manage their complications in the emergency department

Recent studies by Sanofi-Aventis and Eli Lilly in phase 1 and 2, respectively, were the first to report and have stimulated further interest in the field